Q-omics provides the consensus-scored DCAF16 profile across patient tissues and cancer cell-line models. DCAF16 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, DCAF16 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, DCAF16 RNA expression shows 21,377 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, and ACC as cancer lineages where DCAF16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DCAF16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DCAF16 survival associations across molecular data types. DCAF16 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DCAF16 RNA expression–survival associations across cancer types. High DCAF16 expression shows unfavorable associations in LIHC and KIRP, but favorable associations in READ, UCS, BRCA and SCLC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for DCAF16 RNA expression.
This table summarizes DCAF16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in LIHC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for DCAF16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DCAF16 shows lower tumor expression in THCA and KIRC and higher tumor expression in LIHC, HNSC, COAD and LUAD. The LIHC box plot shows higher DCAF16 RNA expression in tumor versus normal tissue (log2 FC = +1.403, t-test p < 0.001).
This table shows molecular features associated with DCAF16 in patient tissues and cancer cell lines. In patient samples, DCAF16 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DCAF16 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_SCLC.
